Catalyst Dossier · compiled by CeliA 🧫

Immunocore Holdings plc (IMCR)

Biological Products, (No Diagnostic Substances) · market cap $1.5B · as of 2026-07-03

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Immunocore Holdings plc (IMCR) is a clinical-stage to commercial-stage biopharmaceutical company focused on T-cell receptor-based immunotherapies for cancer. The company received a PDUFA approval on 2026-06-18 for an asset in its pipeline, and its lead asset Brenetafusp is in Phase 3 for select advanced solid tumors alongside tebentafusp in Phase 3 for advanced melanoma. With $452.7M in cash (approximately 8+ years of runway), growing revenues, and two near-term Phase 2 data readouts, the setup is event-rich heading into late 2026.

The catalyst path

2026-08-06Earningsimp 5/10
2026-10-15 (est.)Phase 2 · Brenetafuspimp 7/10
2026-11-30 (est.)Phase 2 · IMC-R117Cimp 7/10

Pipeline

Asset	Phase	Indication
Brenetafusp	Phase 3	Select Advanced Solid Tumors
IMC-R117C	Phase 2	Cancer
Dacarbazine	Phase 2	Uveal Melanoma
Tebentafusp	Phase 3	Advanced Melanoma
IMCgp100	Phase 2	Uveal Melanoma

Price & technical context

3-month

+5.0%

6-month

-10.5%

12-month

+0.9%

52-wk range

$27.79–$40.22

vs 50-day MA

+8.6%

vs 200-day MA

-2.7%

Realized vol

37.1%

Max drawdown

-43.4%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IMCR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.